Get the Stockscreener App
0.1705
1.45%
-0.0025
After Hours:
.17
-0.0005
-0.29%
Qualigen Therapeutics Inc stock is traded at $0.1705, with a volume of 93,951.
It is down -1.45% in the last 24 hours and down -9.12% over the past month.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
See More
Previous Close:
$0.173
Open:
$0.17
24h Volume:
93,951
Relative Volume:
0.01
Market Cap:
$4.61M
Revenue:
$4.79M
Net Income/Loss:
$-13.42M
P/E Ratio:
-0.0424
EPS:
-4.02
Net Cash Flow:
$-10.30M
1W Performance:
+2.10%
1M Performance:
-9.12%
6M Performance:
-57.38%
1Y Performance:
-83.12%
1-Day Range:
$0.166
$0.1776
1-Week Range:
$0.165
$0.1776
52-Week Range:
$0.141
$1.10
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
Name
Qualigen Therapeutics Inc
Sector
Industry
Phone
(760) 918-9165
Address
2042 CORTE DEL NOGAL, CALIFORNIA
Qualigen Therapeutics Inc Stock (QLGN) Latest News
Qualigen Therapeutics sees major executive reshuffle By Investing.com - Investing.com Canada
Qualigen Therapeutics appoints new leadership amid strategic shift By Investing.com - Investing.com South Africa
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Sees Large Decline in Short Interest - Defense World
Qualigen Therapeutics sees major executive reshuffle By Investing.com - Investing.com Australia
Qualigen Therapeutics sees major executive reshuffle - Investing.com
Qualigen Therapeutics appoints new leadership amid strategic shift - Investing.com
Qualigen Therapeutics appoints new leadership amid strategic shift - Investing.com India
Qualigen Therapeutics sees major executive reshuffle - Investing.com India
Qualigen Therapeutics Announces Executive Shakeup and Board Revamp - TipRanks
Qualigen Therapeutics sees major executive reshuffle By Investing.com - Investing.com UK
Qualigen Therapeutics, Inc. Announces management changes. - The Manila Times
Qualigen Therapeutics appoints new leadership amid strategic shift By Investing.com - Investing.com UK
Qualigen Therapeutics, Inc. Announces management changes. - GlobeNewswire
Qualigen Therapeutics, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Stock Surge: Qualigen Therapeutics Inc (QLGN) Closes at 0.17, Marking a -4.84 Increase/Decrease - The Dwinnex
Qualigen Therapeutics granted Nasdaq listing extension - Investing.com
Qualigen Therapeutics granted Nasdaq listing extension By Investing.com - Investing.com Australia
Qualigen Therapeutics receives extension from Nasdaq hearings panel - TipRanks
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - GlobeNewswire
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - Yahoo Finance
Garner Asset Management Corp Purchases 1,151 Shares of QUALCOMM Incorporated (NASDAQ:QCOM) - Defense World
Quorn faces £63.4m loss as UK and US meat-free market sales decline - Express
QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity - Zacks Investment Research
Choreo LLC Makes New $264,000 Investment in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Quorn: Meat-free food brand loses more than £60m as supermarket sales slashed - City A.M.
Qiagen NV (QGEN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Qiagen (NYSE:QGEN) Sees Large Volume Increase - Defense World
Balance Sheet Breakdown: Qiagen NV (QGEN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Federated Hermes Inc. Raises Position in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Bokf Na Increases Stock Position in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Qsemble Capital Management LP Invests $332,000 in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Quest Partners LLC Increases Position in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Caprock Group LLC Decreases Stock Holdings in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - ForexTV.com
Univest Securities, LLC Announces Closing of $3.46 Million - GlobeNewswire
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - Yahoo Finance
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering - GlobeNewswire
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering - EIN News
SEC Form 424B4 filed by Qualigen Therapeutics Inc. - Quantisnow
Ratio Examination: Qualigen Therapeutics Inc (QLGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering - ForexTV.com
Qualigen Therapeutics sets public offering at $0.13 per share - Investing.com
QLGN stock touches 52-week low at $0.14 amid market challenges - Investing.com
Qualigen Therapeutics Inc (QLGN) Stock: A Year of Market Fluctuations - The InvestChronicle
US Stocks Edge Higher; Jobless Claims Fall To 227,000 - Benzinga
Qualigen Therapeutics prices 14.7M shares at 13c in public offering - TipRanks
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering - GlobeNewswire
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering - GlobeNewswire Inc.
Qualigen Therapeutics Inc (QLGN) stock on the rise: An overview - US Post News
An analyst sees good growth prospects for Qualigen Therapeutics Inc (QLGN) - SETE News
Qualigen Therapeutics Inc (QLGN) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Qualigen Therapeutics Inc Stock (QLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):